Population pharmacokinetics and target attainment analysis of linezolid in multidrug-resistant tuberculosis patients.
Anna Katharina TietjenNiklas KroemerDario CattaneoSara BaldelliSebastian Georg WichaPublished in: British journal of clinical pharmacology (2021)
This study showed that a dose of 300 mg twice daily of linezolid might not be sufficient to treat MDR-TB patients from a PK/PD perspective. Thus, it might be recommendable to start with a higher dose of 600 mg twice daily to ensure PK/PD target attainment. Hereby, therapeutic drug monitoring and MIC determination should be performed to control PK/PD target attainment as linezolid shows high variability in its PK in the TB population.
Keyphrases
- multidrug resistant
- end stage renal disease
- ejection fraction
- newly diagnosed
- mycobacterium tuberculosis
- chronic kidney disease
- physical activity
- methicillin resistant staphylococcus aureus
- escherichia coli
- patient reported outcomes
- staphylococcus aureus
- pulmonary tuberculosis
- high resolution
- patient reported
- antiretroviral therapy
- electronic health record
- solid phase extraction
- molecularly imprinted